NousCom receives $49M to trial off-the-shelf cancer vaccine
Cancer vaccine startup NousCom has raised €42 million ($49 million). The round equips a team last seen leading Okairos to a €250 million buyout by GlaxoSmithKline to take off-the-shelf neoantigen cancer vaccine NOUS-209 into the clinic. Basel, Switzerland-based NousCom’s near-term prospects rest on programs based on Exovax. The Exovax platform uses single adenovirus vectors that […]